Morgan Stanley An2 Therapeutics, Inc. Transaction History
Morgan Stanley
- $1.23 Trillion
- Q1 2024
A detailed history of Morgan Stanley transactions in An2 Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 4,164 shares of ANTX stock, worth $8,952. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,164
Previous 3,331
25.01%
Holding current value
$8,952
Previous $68,000
80.88%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ANTX
# of Institutions
55Shares Held
13.2MCall Options Held
0Put Options Held
0-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$3.35 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$3.34 Million0.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA1.39MShares$2.99 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA1.24MShares$2.66 Million0.12% of portfolio
-
Janus Henderson Group PLC London, X01.22MShares$2.63 Million0.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $41.7M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...